Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 24

Sort by

Sort Order Select

Journal Articles

Targeting CDK16 Abrogates Growth-Factor Mediated TKI Resistance in AML

Meenu Kesarwani, Zachary Kincaid, Mohammad Azhar, Mohammad Azam

Blood (2024) 144 (Supplement 1): 5786.

https://doi.org/10.1182/blood-2024-211448

Published: 2024

Journal Articles

Enhanced Mitochondrial Priming By Momelotinib Confers Superior In Vivo Efficacy in Combination with Venetoclax Compared to Gilteritinib or Ruxolitinib

Zachary Kincaid, Sekhu Ansari, Mohammad Azhar, Meenu Kesarwani, Mohammad Azam

Blood (2024) 144 (Supplement 1): 5814.

https://doi.org/10.1182/blood-2024-211412

Published: 2024

Journal Articles

A Novel BCR::ABL1 Rearrangement Harboring the Gatekeeper Mutation Drives Hyper-Kinase Activity Conferring Resistance to Ponatinib and Asciminib Combination Therapy

Valentina Nardi, Joshua Schwieterman, Zachary Kincaid, Andrew M. Brunner, Maria Reyes, Gabriel K. Griffin, Sekhu Ansari, Mohammad Azam

Blood (2024) 144 (Supplement 1): 4541.

https://doi.org/10.1182/blood-2024-211279

Published: 2024

Journal Articles

DUSP1 Specific Protac Selectively Targets the JAK2 V617F Expressing Cells

Meenu Kesarwani, Mohammad Azhar, Sekhu Ansari, Zachary Kincaid, Mohammad Azam

Blood (2023) 142 (Supplement 1): 3156.

https://doi.org/10.1182/blood-2023-189845

Published: 2023

Journal Articles

Targeting the Negative-Feedback Inhibitor of MAPK Signaling Selectively Eliminates Leukemic Clone in Cnl/Acml

Meenu Kesarwani, Mohammad Azhar, Zachary Kincaid, Mohammad Azam

Blood (2022) 140 (Supplement 1): 9582–9583.

https://doi.org/10.1182/blood-2022-167291

Published: 2022

Journal Articles

Rational Polypharmacological Targeting of FLT3, JAK2, ABL and ERK1 By Pluripotin Suppresses the Adaptive Resistance to FLT3 Inhibitors in AML

Mohammad Azhar, Zachary Kincaid, Meenu Kesarwani, Tahir Latif, Sekhu Ansari, William Seibel, Mohammad Azam

Blood (2022) 140 (Supplement 1): 3101–3102.

https://doi.org/10.1182/blood-2022-167484

Published: 2022

Journal Articles

PLaCatinG AML1-ETO

Mohammad Azam

Blood (2022) 139 (7): 959–961.

https://doi.org/10.1182/blood.2021014416

Published: 2022

Journal Articles

Momelotinib Is a Highly Potent Inhibitor of FLT3-Mutant AML

Mohammad Azhar, Zachary Kincaid, Meenu Kesarwani, Mark Wunderlich, Tahir Latif, Daniel Starczynowski, Mohammad Azam

Blood (2021) 138 (Supplement 1): 206.

https://doi.org/10.1182/blood-2021-148822

Published: 2021

Journal Articles

Loss of DUSP1 Is Synthetic Lethal to JAK2 V617F

Meenu Kesarwani, Zachary Kincaid, BS, Tahir Latif, MD, Mohammad Azam, PhD

Blood (2018) 132 (Supplement 1): 51.

https://doi.org/10.1182/blood-2018-99-115503

Published: 2018

Journal Articles

DUSP1 Confers Oncogene Dependence in CSF3R Induced Leukemia

Meenu Kesarwani, Zachary Kincaid, BS, Mohammad Azam, PhD

Blood (2018) 132 (Supplement 1): 1341.

https://doi.org/10.1182/blood-2018-99-119092

Published: 2018

Journal Articles

A Common Signaling Node Constitute Non-Oncogene Addiction in Kinase Driven Leukemia:Mechanism of Oncogne Addiction in CML

Meenu Kesarwani, PhD, Zachary Kincaid, BS, Ahmed Ramadan Gomma, PhD, Erika Huber, Sara Rohrabaugh, PhD, H. Leighton Grimes, PhD, Mohammad Azam, PhD

Blood (2016) 128 (22): 3056.

https://doi.org/10.1182/blood.V128.22.3056.3056

Published: 2016

Journal Articles

Compound Heterozygosity of Two Novel JAK2 Mutations in Hereditary Essential Thrombocythemia Implicates Important Monomer-Monomer Interactions in Thrombopoiesis Signaling

Kiersten Ricci, MD, Erika Huber, Ashok Raj, MD, Mohammad Azam, PhD, Theodosia A. Kalfa, MD PhD

Blood (2016) 128 (22): 3137.

https://doi.org/10.1182/blood.V128.22.3137.3137

Published: 2016

Journal Articles

Enhanced MAPK Signaling Constitute Non-Oncogene Addiction in CSF3R Induced Leukemia

Sara Rohrabaugh, PhD, Meenu Kesarwani, PhD, Zachary Kincaid, BS, Erika Huber, H. Leighton Grimes, PhD, Mohammad Azam, PhD

Blood (2016) 128 (22): 632.

https://doi.org/10.1182/blood.V128.22.632.632

Published: 2016

Journal Articles

Overcoming Drug Resistance Of FLT3-ITD By SAR302503

Meenu Kesarwani, PhD, Erika Huber, BS, Mohammad Azam, PhD

Blood (2013) 122 (21): 5023.

https://doi.org/10.1182/blood.V122.21.5023.5023

Published: 2013

Journal Articles

Targeting the Genetic Resistance of JAK2 and BCR/ABL by TG101348

Meenu Kesarwani, PhD, Mohammad Azam, PhD

Blood (2012) 120 (21): 3765.

https://doi.org/10.1182/blood.V120.21.3765.3765

Published: 2012

Journal Articles

Mechanisms of Drug Resistance Against JAK2 Inhibitors

Mohammad Azam, PhD

Blood (2011) 118 (21): 1426.

https://doi.org/10.1182/blood.V118.21.1426.1426

Published: 2011

Journal Articles

ICSBP-mediated immune protection against BCR-ABL–induced leukemia requires the CCL6 and CCL9 chemokines

Valentina Nardi, Olaia Naveiras, Mohammad Azam, George Q. Daley

Blood (2009) 113 (16): 3813–3820.

https://doi.org/10.1182/blood-2008-07-167189

Published: 2009

Includes: Supplemental data

Journal Articles

Inhibition of BCR/ABL-T315I by Dismantling the Hydrophobic Spine.

Mohammad Azam, PhD, Markus Seeliger, John T Powers, Nathanael Gray, John Kuriyan, Ph.D., George Q. Daley, MD, PhD

Blood (2008) 112 (11): 2129.

https://doi.org/10.1182/blood.V112.11.2129.2129

Published: 2008

Journal Articles

A Unified Mechanism of Tyrosine Kinase Regulation by the Gatekeeper Residue.

Mohammad Azam, PhD, Markus Seeliger, PhD, Nathanael S. Gray, PhD, John Kuriyan, PhD, George Q. Daley, MD, PhD

Blood (2007) 110 (11): 223.

https://doi.org/10.1182/blood.V110.11.223.223

Published: 2007

Journal Articles

A Critical Role for CCL Chemokines in the Immuno-Protection Induced by Type I Interferons and IRF8/ICSBP Against Bcr/Abl-Induced Leukemia.

Valentina Nardi, MD, Olaia Naveiras, MD, Mohammad Azam, PhD, George Q. Daley, MD, PhD

Blood (2007) 110 (11): 1001.

https://doi.org/10.1182/blood.V110.11.1001.1001

Published: 2007

NARROW

Targeting CDK16 Abrogates Growth-Factor Mediated TKI Resistance in AML

Enhanced Mitochondrial Priming By Momelotinib Confers Superior In Vivo Efficacy in Combination with Venetoclax Compared to Gilteritinib or Ruxolitinib

A Novel BCR::ABL1 Rearrangement Harboring the Gatekeeper Mutation Drives Hyper-Kinase Activity Conferring Resistance to Ponatinib and Asciminib Combination Therapy

DUSP1 Specific Protac Selectively Targets the JAK2 V617F Expressing Cells

Targeting the Negative-Feedback Inhibitor of MAPK Signaling Selectively Eliminates Leukemic Clone in Cnl/Acml

Rational Polypharmacological Targeting of FLT3, JAK2, ABL and ERK1 By Pluripotin Suppresses the Adaptive Resistance to FLT3 Inhibitors in AML

PLaCatinG AML1-ETO

Momelotinib Is a Highly Potent Inhibitor of FLT3-Mutant AML

Loss of DUSP1 Is Synthetic Lethal to JAK2 V617F

DUSP1 Confers Oncogene Dependence in CSF3R Induced Leukemia

A Common Signaling Node Constitute Non-Oncogene Addiction in Kinase Driven Leukemia:Mechanism of Oncogne Addiction in CML

Compound Heterozygosity of Two Novel JAK2 Mutations in Hereditary Essential Thrombocythemia Implicates Important Monomer-Monomer Interactions in Thrombopoiesis Signaling

Enhanced MAPK Signaling Constitute Non-Oncogene Addiction in CSF3R Induced Leukemia

Overcoming Drug Resistance Of FLT3-ITD By SAR302503

Targeting the Genetic Resistance of JAK2 and BCR/ABL by TG101348

Mechanisms of Drug Resistance Against JAK2 Inhibitors

ICSBP-mediated immune protection against BCR-ABL–induced leukemia requires the CCL6 and CCL9 chemokines

Inhibition of BCR/ABL-T315I by Dismantling the Hydrophobic Spine.

A Unified Mechanism of Tyrosine Kinase Regulation by the Gatekeeper Residue.

A Critical Role for CCL Chemokines in the Immuno-Protection Induced by Type I Interferons and IRF8/ICSBP Against Bcr/Abl-Induced Leukemia.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only